EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib By Ogkologos - May 22, 2026 3 0 Facebook Twitter Google+ Pinterest WhatsApp Palbociclib Viatris is a generic of Ibrance which has been authorised in the EU since 2016 Source RELATED ARTICLESMORE FROM AUTHOR Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC FDA Approves Zenocutuzumab-zbco for Advanced, Unresectable or Metastatic Cholangiocarcinoma MOST POPULAR Limited Efficacy of Nivolumab plus Ipilimumab in Adenoid Cystic Carcinomas, but... September 11, 2023 FDA Approves Idecabtagene Vicleucel for Multiple Myeloma April 7, 2021 Topotecan–Berzosertib Combination Shows Promise against Small Cell Lung Cancer May 5, 2021 Mother Of 6 With ‘Open-Door Policy’ Packs 100 Lunches For Hungry... September 18, 2019 Load more HOT NEWS FDA Grants Accelerated Approval to Dabrafenib in Combination with Trametinib for... Stringently Defined Clinical Complete Response After Gemcitabine, Cisplatin, Plus Nivolumab Facilitates... Why consistent and funded cancer policies are key to improving cancer... ESMO AI & Digital Oncology Congress 2025 Closed in Berlin under...
